Evaluation of terminal complement cascade inhibitors using in vitro and in vivo models of age-related macular degeneration and in Alzheimer’s Disease

Age-related macular degeneration (AMD) is a leading cause of blindness that is estimated to affect over 6 million people globally. There are currently no approved treatments for dry AMD, the most common form of the disease. Various lines of inquiry suggest that dysregulation of a part of the innate immune system called complement plays a key role in the progression of AMD. This research project aims to (a) further explore the underlying causes of the disease, and (b) evaluate potential treatments in pre-clinical studies. Interns will conduct laboratory experiments using model systems and investigational drugs. Research results will help guide the partner organization’s drug development program.

Gideon Obasanmi
Faculty Supervisor: 
Joanne Matsubara
British Columbia
Partner University: